{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:57:12Z","timestamp":1792900632193,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR001085"],"award-info":[{"award-number":["UL1 TR001085"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006352","name":"Virginia and D K Ludwig Fund for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006535","name":"Entertainment Industry Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006535","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000043","name":"American Association for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"Stand Up To Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014547","name":"Parker Institute for Cancer Immunotherapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006058","name":"Saint Baldricks Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005492","name":"Stanford University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.eclinm.2023.102268","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T23:30:53Z","timestamp":1698276653000},"page":"102268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns"],"prefix":"10.1016","volume":"65","author":[{"given":"Valentin","family":"Barsan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snehit","family":"Prabhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Baggott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0688-8651","authenticated-orcid":false,"given":"Khanh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Pacenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Rossoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Stefanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie-An","family":"Talano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Moskop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Baumeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Verneris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary Douglas","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole A.","family":"Karras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muna","family":"Qayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Hermiston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Satwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Krupski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Fabrizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasant","family":"Chinnabhandar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kunicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0359-9023","authenticated-orcid":false,"given":"Crystal L.","family":"Mackall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore W.","family":"Laetsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liora M.","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2023.102268_bib1","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/S2352-3026(19)30003-1","article-title":"Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial","volume":"6","author":"Parker","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.eclinm.2023.102268_bib2","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(12)70580-6","article-title":"Relapsed childhood acute lymphoblastic leukaemia","volume":"14","author":"Bhojwani","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2023.102268_bib3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3324\/haematol.2019.237230","article-title":"Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433","volume":"106","author":"Lew","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.eclinm.2023.102268_bib4","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood.2019004043","article-title":"How I treat relapsed acute lymphoblastic leukemia in the pediatric population","volume":"136","author":"Hunger","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102268_bib5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3324\/haematol.2015.131680","article-title":"Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome","volume":"101","author":"Oskarsson","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.eclinm.2023.102268_bib6","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/s41375-018-0094-0","article-title":"Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study","volume":"32","author":"Sun","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.eclinm.2023.102268_bib7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/leu.2009.250","article-title":"Long-term results of the Italian association of pediatric hematology and oncology (AIEOP) studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia","volume":"24","author":"Conter","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.eclinm.2023.102268_bib8","doi-asserted-by":"crossref","first-page":"10008","DOI":"10.1200\/JCO.2019.37.15_suppl.10008","article-title":"Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): a Children's Oncology Group (COG) study","volume":"37","author":"Rheingold","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2023.102268_bib9","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","article-title":"Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232","volume":"126","author":"Borowitz","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102268_bib10","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102268_bib11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2002-01-0006","article-title":"Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia","volume":"100","author":"Coustan-Smith","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102268_bib12","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation","volume":"360","author":"Pui","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2023.102268_bib13","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2023.102268_bib14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2023.102268_bib15","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102268_bib16","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1182\/blood.2021012328","article-title":"Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium","volume":"139","author":"Buchmann","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102268_bib17","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102268_bib18","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1182\/blood.V99.6.1952","article-title":"Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia","volume":"99","author":"Dworzak","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102268_bib19","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2017-09-806521","article-title":"Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL","volume":"131","author":"Wood","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102268_bib20","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.eclinm.2023.102268_bib21","first-page":"292","article-title":"Minimal residual disease as a surrogate marker for risk assignment to ALL patients","volume":"7","author":"Cazzaniga","year":"2003","journal-title":"Rev Clin Exp Hematol"},{"key":"10.1016\/j.eclinm.2023.102268_bib22","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood.V95.3.790.003k48_790_794","article-title":"Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia","volume":"95","author":"Panzer-Gr\u00fcmayer","year":"2000","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102268_bib23","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult b-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2023.102268_bib24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.eclinm.2023.102268_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eclinm.2023.102268_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26871","article-title":"An investigation of toxicities and survival in Hispanic children and adolescents with ALL: results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001","volume":"65","author":"Kahn","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.eclinm.2023.102268_bib27","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1200\/EDBK_320499","article-title":"Disparities in pediatric oncology: the 21st century opportunity to improve outcomes for children and adolescents with cancer","volume":"41","author":"Aristizabal","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.eclinm.2023.102268_bib28","article-title":"Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia","volume":"9","author":"Levine","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.eclinm.2023.102268_bib29","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2023.102268_bib30","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jpeds.2018.07.039","article-title":"Next-generation evaluation and treatment of pediatric acute lymphoblastic leukemia","volume":"203","author":"Heikamp","year":"2018","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.eclinm.2023.102268_bib31","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2011-03-341412","article-title":"Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"118","author":"Zhang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102268_bib32","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1182\/blood-2016-03-704973","article-title":"Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia","volume":"128","author":"Irving","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102268_bib33","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1038\/leu.2008.227","article-title":"Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia","volume":"22","author":"Paganin","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.eclinm.2023.102268_bib34","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eclinm.2023.102268_bib35","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1182\/bloodadvances.2022007378","article-title":"High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse","volume":"6","author":"Short","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.eclinm.2023.102268_bib36","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102268_bib37","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102268_bib38","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2023.102268_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2019.101095","article-title":"How advanced are we in targeting novel subtypes of ALL?","volume":"32","author":"Mullighan","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.eclinm.2023.102268_bib40","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s11899-018-0470-x","article-title":"CAR-T cell therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease","volume":"13","author":"Pehlivan","year":"2018","journal-title":"Curr Hematol Malig Rep"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023004455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023004455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:21:24Z","timestamp":1762899684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537023004455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":40,"alternative-id":["S2589537023004455"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102268","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102268","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102268"}}